Guzman Y Gomez: It’s not just the burritos that are expensive, so is the stock!
Marc Kennis, June 21, 2024
The Guzman Y Gomez IPO was a success, but the stock is expensive
Stuart Roberts from Stocks Down Under gives his take on the newly public company, Guzman Y Gomez (ASX: GYG). He admits to being a patron himself but expresses concern over the company’s high valuation, comparing it to Domino’s (ASX: DMP) and highlighting its pricey quick service restaurant format. Despite the restaurant chain being well-executed, Stuart considers it overpriced, and anticipates more decline after an initial drop of 5%.
Stuart further discusses the vulnerability of the company in the face of consumer shifts like those seen with Domino’s (ASX: DMP). He remarks that cost of living pressures can redirect customers to long-standing reliable outlets such as McDonald’s. Stuart also feels sceptical of Guzman’s (ASX: GYG) high-growth projections given their current climate of consumer sentiment and living costs.
Better value in Life Sciences
Lastly, Stuart brings attention to Botanix Pharmaceuticals (ASX: BOT), a company he finds lacks the recognition it deserves despite its FDA approved drug for an underserved medical condition. He encourages investors who profited from Guzman (ASX: GYG) to consider investing in Botanix Pharmaceuticals (ASX: BOT). Despite acknowledging the potential for Guzman’s (ASX: GYG) success, as was the unexpected case for Starbucks years ago, Stuart maintains his reservations about the company’s valuation.
Watch the full interview here!
What are the Best ASX Fast Food Stocks to invest in right now?
Check our ASX buy/sell tips
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…
CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know
In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…